Changes in the epidemiological trends of primary liver cancer in the Asia-Pacific region.
Alcohol-associated liver disease
Asia–Pacific
Epidemiology
Liver cancer
Metabolic dysfunction-associated steatotic liver disease
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 08 2024
22 08 2024
Historique:
received:
24
05
2024
accepted:
19
08
2024
medline:
23
8
2024
pubmed:
23
8
2024
entrez:
22
8
2024
Statut:
epublish
Résumé
Primary liver cancer is the third leading cause of cancer-related mortality. The increasing prevalence of metabolic syndrome and alcohol consumption, along with the existing burden of viral hepatitis, could significantly heighten the impact of primary liver cancer. However, the specific effects of these factors in the Asia-Pacific region, which comprises more than half of the global population, remain largely unexplored. This study aims to analyze the epidemiology of primary liver cancer in the Asia-Pacific region. We evaluated regional and national data from the Global Burden of Disease study spanning 2010 to 2019 to assess the age-standardized incidence, mortality, and disability-adjusted life years associated with primary liver cancer in the Asia-Pacific region. During the study period, there were an estimated 364,700 new cases of primary liver cancer and 324,100 deaths, accounting for 68 and 67% of the global totals, respectively. Upward trends were observed in the age-standardized incidence rates of primary liver cancer due to metabolic dysfunction-associated fatty liver disease (MASLD) and alcohol-associated liver disease (ALD) in the Asia-Pacific region, as well as an increase in primary liver cancer from Hepatitis B virus infection in the Western Pacific region. Notably, approximately 17% of new cases occurred in individuals aged 15-49 years. Despite an overall decline in the burden of primary liver cancer in the Asia-Pacific region over the past decade, increases in incidence were noted for several etiologies, including MASLD and ALD. However, viral hepatitis remains the leading cause, responsible for over 60% of the total burden. These findings underscore the urgent need for comprehensive strategies to address the rising burden of primary liver cancer in the Asia-Pacific region.
Identifiants
pubmed: 39174722
doi: 10.1038/s41598-024-70526-z
pii: 10.1038/s41598-024-70526-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19544Informations de copyright
© 2024. The Author(s).
Références
Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers. 7(1), 6 (2021).
pubmed: 33479224
doi: 10.1038/s41572-020-00240-3
Buettner, S., van Vugt, J. L., IJzermans, J. N. & Groot Koerkamp, B. Intrahepatic cholangiocarcinoma: current perspectives. Onco Targets Ther. 10, 1131–42 (2017).
pubmed: 28260927
pmcid: 5328612
doi: 10.2147/OTT.S93629
Altekruse, S. F., Devesa, S. S., Dickie, L. A., McGlynn, K. A. & Kleiner, D. E. Histological classification of liver and intrahepatic bile duct cancers in SEER registries. J. Regist. Manag. 38(4), 201–205 (2011).
Rumgay, H. et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J. Hepatol. 77(6), 1598–1606 (2022).
pubmed: 36208844
pmcid: 9670241
doi: 10.1016/j.jhep.2022.08.021
McGlynn, K. A., Petrick, J. L. & El-Serag, H. B. Epidemiology of hepatocellular carcinoma. Hepatology. 73(Supp 1), 4–13 (2021).
pubmed: 32319693
doi: 10.1002/hep.31288
Konyn, P., Ahmed, A. & Kim, D. Current epidemiology in hepatocellular carcinoma. Expert Rev. Gastroenterol. Hepatol. 15(11), 1295–1307 (2021).
pubmed: 34624198
doi: 10.1080/17474124.2021.1991792
Asia-Pacific Population and Development Report 2023. Bangkok: Social Development Division, Economic and Social Commission for Asia and the Pacific (ESCAP), United Nations (2023).
Danpanichkul, P. et al. Global and regional burden of alcohol-associated liver disease and alcohol use disorder in the elderly. JHEP Rep. 6(4), 101020 (2024).
pubmed: 38515553
pmcid: 10956070
doi: 10.1016/j.jhepr.2024.101020
Danpanichkul, P. et al. The surreptitious burden of nonalcoholic fatty liver disease in the elderly in the asia-pacific region: An insight from the global burden of disease study 2019. J. Clin. Med. 12(20), 6456 (2023).
pubmed: 37892594
pmcid: 10607093
doi: 10.3390/jcm12206456
Danpanichkul, P. et al. The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysis. Aliment. Pharmacol. Ther. 58(10), 1062–1074 (2023).
pubmed: 37694808
doi: 10.1111/apt.17714
Danpanichkul, P. et al. Global and regional burden of alcohol-associated liver disease and alcohol use disorder in the elderly. JHEP Rep. 6(4), 101020 (2024).
pubmed: 38515553
pmcid: 10956070
doi: 10.1016/j.jhepr.2024.101020
Kitiyakara, T. et al. Regional differences in admissions and treatment outcomes for hepatocellular carcinoma patients in Thailand. Asian Pac. J. Cancer Prev. 23(11), 3701–3715 (2022).
pubmed: 36444583
pmcid: 9930940
doi: 10.31557/APJCP.2022.23.11.3701
Zheng, R. et al. Liver cancer incidence and mortality in China: Temporal trends and projections to 2030. Chin. J. Cancer Res. 30(6), 571–579 (2018).
pubmed: 30700925
pmcid: 6328503
doi: 10.21147/j.issn.1000-9604.2018.06.01
Collaborators, G. B. D. H. B. Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol. Hepatol. 7(9), 796–829 (2022).
doi: 10.1016/S2468-1253(22)00124-8
Collaborators, G. B. D. R. F. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 396(10258), 1223–49 (2020).
doi: 10.1016/S0140-6736(20)30752-2
Liu, Y. et al. Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019. Cancer Med. 11(5), 1310–1323 (2022).
pubmed: 35118819
pmcid: 8894698
doi: 10.1002/cam4.4551
Diseases, G. B. D. & Injuries, C. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 396(10258), 1204–1222 (2020).
doi: 10.1016/S0140-6736(20)30925-9
Huang, D. Q. et al. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 34(7), 969–77.e2 (2022).
pubmed: 35793659
pmcid: 9762323
doi: 10.1016/j.cmet.2022.05.003
Song, S. J., Lai, J. C., Wong, G. L., Wong, V. W. & Yip, T. C. Can we use old NAFLD data under the new MASLD definition?. J. Hepatol. 80(2), e54–e56 (2024).
pubmed: 37541393
doi: 10.1016/j.jhep.2023.07.021
Younossi, Z. M. et al. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J. Hepatol. 80(5), 694–701 (2024).
pubmed: 38286339
doi: 10.1016/j.jhep.2024.01.014
Suzuki, H., Tsutsumi, T., Kawaguchi, M., Amano, K., Kawaguchi, T. Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia. Clin. Mol. Hepatol. (2024).
Danpanichkul, P. et al. The global burden of early-onset biliary tract cancer: Insight from the global burden of disease study 2019. J. Clin. Exp. Hepatol. 14(2), 101320 (2024).
pubmed: 38261906
doi: 10.1016/j.jceh.2023.101320
Danpanichkul, P. et al. Rising incidence and impact of early-onset colorectal cancer in the Asia-Pacific with higher mortality in females from Southeast Asia: A global burden analysis from 2010 to 2019. J. Gastroenterol. Hepatol. 38(12), 2053–2060 (2023).
pubmed: 37644698
doi: 10.1111/jgh.16331
Danpanichkul, P., Ng, C. H., Hao Tan, D. J., Wijarnpreecha, K., Huang, D. Q., Noureddin, M., et al. The global burden of alcohol-associated cirrhosis and cancer in young and middle-aged adults. Clin. Gastroenterol. Hepatol. (2024).
LaPelusa, M., Shen, C., Arhin, N. D., Cardin, D., Tan, M., Idrees, K., et al. Trends in the incidence and treatment of early-onset pancreatic Cancer. Cancers (Basel). 14(2) (2022).
Cao, G., Liu, J. & Liu, M. Global, regional, and national trends in incidence and mortality of primary liver cancer and its underlying etiologies from 1990 to 2019: Results from the global burden of disease study 2019. J. Epidemiol. Glob. Health. 13(2), 344–360 (2023).
pubmed: 37178451
pmcid: 10271958
doi: 10.1007/s44197-023-00109-0
Karim, M. A. et al. Clinical characteristics and outcomes of nonalcoholic fatty liver disease-associated hepatocellular carcinoma in the United States. Cli. Gastroenterol. Hepatol. 21(3), 670-680.e18 (2023).
doi: 10.1016/j.cgh.2022.03.010
Trepo, C., Chan, H. L. & Lok, A. Hepatitis B virus infection. Lancet. 384(9959), 2053–2063 (2014).
pubmed: 24954675
doi: 10.1016/S0140-6736(14)60220-8
Nawaz, A. et al. Therapeutic approaches for chronic hepatitis C: A concise review. Front. Pharmacol. 14, 1334160 (2023).
pubmed: 38283838
doi: 10.3389/fphar.2023.1334160
Sripongpun, P. et al. Hepatitis C screening in post-baby boomer generation Americans: one size does not fit all. Mayo Clin. Proc. 98(9), 1335–1344 (2023).
pubmed: 37661141
doi: 10.1016/j.mayocp.2023.02.009
Lok, A. S. Progress in hepatitis B: A 30-year journey through three continents. Hepatology. 60(1), 4–11 (2014).
pubmed: 24619499
doi: 10.1002/hep.27120
Chamroonkul, N. & Piratvisuth, T. Hepatitis B during pregnancy in endemic areas: Screening, treatment, and prevention of mother-to-child transmission. Paediatr. Drugs. 19(3), 173–181 (2017).
pubmed: 28434087
doi: 10.1007/s40272-017-0229-1
Sarin, S. K. et al. Liver diseases in the Asia-Pacific region: A lancet gastroenterology & hepatology commission. Lancet Gastroenterol. Hepatol. 5(2), 167–228 (2020).
pubmed: 31852635
doi: 10.1016/S2468-1253(19)30342-5
Tang, Y. L. et al. Alcohol and alcohol-related harm in China: Policy changes needed. Bull. World Health Organ. 91(4), 270–276 (2013).
pubmed: 23599550
pmcid: 3629448
doi: 10.2471/BLT.12.107318
Ranasinghe, P., Mathangasinghe, Y., Jayawardena, R., Hills, A. P. & Misra, A. Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: A systematic review. BMC Public Health. 17(1), 101 (2017).
pubmed: 28109251
pmcid: 5251315
doi: 10.1186/s12889-017-4041-1
Danpanichkul, P. et al. The burden of overweight and obesity-associated gastrointestinal cancers in low and lower-middle-income countries: A global burden of disease 2019 analysis. Am. J. Gastroenterol. 119(6), 1177–1180 (2024).
pubmed: 38900306
doi: 10.14309/ajg.0000000000002819
Lazarus, J. V. et al. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. J. Hepatol. 76(4), 771–780 (2022).
pubmed: 34895743
doi: 10.1016/j.jhep.2021.10.025
Diaz, L. A. et al. Impact of public health policies on alcohol-associated liver disease in Latin America: An ecological multinational study. Hepatology. 74(5), 2478–2490 (2021).
pubmed: 34134172
doi: 10.1002/hep.32016
Diaz, L. A. et al. Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes. J. Hepatol. 80(3), 409–418 (2024).
pubmed: 37992972
doi: 10.1016/j.jhep.2023.11.006
Danpanichkul, P., Duangsonk, K., Diaz, L. A., Arab, J. P., Liangpunsakul, S., Wijarnpreecha, K. Editorial: Sounding the alarm-The rising global burden of adolescent and young adult alcohol-related liver disease. Author's reply. Aliment. Pharmacol. Ther. (2024).
Zeng, R. W., Ong, C. E. Y., Ong, E. Y. H., Chung, C. H., Lim, W. H., Xiao, J., Danpanichkul, P., Law, J. H., Syn, N., Chee, D., Kow, A. W. C., Lee, S. W, Takahashi, H., Kawaguchi, T., Tamaki, N., Dan, Y. Y, Nakajima, A., Wijarnpreecha, K., Muthiah, M. D, Noureddin, M, Loomba, R., Ioannou, G. N., Tan, D. J. H., Ng, C. H., Huang, D. Q. Global prevalence, clinical characteristics, surveillance, treatment allocation, and outcomes of alcohol-associated hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. (2024).
Tan, D. J. H. et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 23(4), 521–530 (2022).
pubmed: 35255263
pmcid: 9718369
doi: 10.1016/S1470-2045(22)00078-X
Israelsen, M., Rungratanawanich, W., Thiele, M., Liangpunsakul, S. Non-invasive tests for alcohol-associated liver disease. Hepatology. (2024).
Preechathammawong, N., Charoenpitakchai, M., Wongsason, N., Karuehardsuwan, J., Prasoppokakorn, T., Pitisuttithum, P., et al. Development of a diagnostic support system for the fibrosis of nonalcoholic fatty liver disease using artificial intelligence and deep learning. Kaohsiung J. Med. Sci. (2024).
Danpanichkul, P., Aboona, M. B., Sukphutanan, B., Kongarin, S., Duangsonk, K., Ng, C. H., et al. Incidence of liver cancer in young adults according to the global burden of disease database 2019. Hepatology. (2024).
Balachandran, A., de Beer, J., James, K. S., van Wissen, L. & Janssen, F. Comparison of population aging in Europe and Asia using a time-consistent and comparative aging measure. J. Aging Health. 32(5–6), 340–351 (2020).
pubmed: 30651037
doi: 10.1177/0898264318824180
Wu, C. W. & Lui, R. N. Early-onset colorectal cancer: Current insights and future directions. World J. Gastrointest. Oncol. 14(1), 230–241 (2022).
pubmed: 35116113
pmcid: 8790420
doi: 10.4251/wjgo.v14.i1.230
Milne, A. N. & Offerhaus, G. J. Early-onset gastric cancer: Learning lessons from the young. World J. Gastrointest. Oncol. 2(2), 59–64 (2010).
pubmed: 21160922
pmcid: 2998932
doi: 10.4251/wjgo.v2.i2.59
Nguyen, H. T., Zheng, A., Gugel, A. & Kistin, C. J. Asians and Asian subgroups are underrepresented in medical research studies published in high-impact generalist journals. J. Immigr. Minor. Health. 23(3), 646–649 (2021).
pubmed: 33515160
pmcid: 8076062
doi: 10.1007/s10903-021-01142-6
Alhashimi, F. H., Khabour, O. F., Alzoubi, K. H. & Al-Shatnawi, S. F. Attitudes and beliefs related to reporting alcohol consumption in research studies: a case from Jordan. Pragmat. Obs. Res. 9, 55–61 (2018).
pubmed: 30349418
pmcid: 6190630
Israelsen, M. et al. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol. Hepatol. 9(3), 218–228 (2024).
pubmed: 38218202
doi: 10.1016/S2468-1253(23)00443-0
Danpanichkul, P., Suparan, K., Kim, D., Wijarnpreecha, K. What is new in metabolic dysfunction-associated steatotic liver disease in lean individuals: From bench to bedside. J. Clin. Med. 13(1) (2024).
Hagstrom, H., Adams, L. A., Allen, A. M., Byrne, C. D., Chang, Y., Duseja, A., et al. The future of international classification of diseases coding in steatotic liver disease: An expert panel Delphi consensus statement. Hepatol. Commun. 8(2) (2024).
Mejia, J. C. & Pasko, J. Primary liver cancers: Intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Surg. Clin. North Am. 100(3), 535–549 (2020).
pubmed: 32402299
doi: 10.1016/j.suc.2020.02.013
Danpanichkul, P. et al. Global epidemiology of alcohol-associated liver disease in adolescents and young adults. Aliment Pharmacol. Ther. 60(3), 378–388. https://doi.org/10.1111/apt.18101 (2024).
pubmed: 38828940
doi: 10.1111/apt.18101